

# IMPROVE

Framework to IMPROVE the Integration of Patient Generated Health Data to Facilitate Value Based Healthcare

## D3.3: Scientific, policies and practices development

Version 1.0

Authors:

Frans Folkvord (PBY)

Jim Carlson Ingebretsen (PBY)

Rens van de Schoot (UU)

## Document Control Sheet

Deliverable Number	D3.3
Deliverable Responsible	UPM
Work Package	WP3
Lead Editor	Frans Folkvord
Internal Reviewer(s)	Manuel Ottaviano (UPM), Liss Hernández (UPM)

## History of Changes

Date	Version/Page	Change
24.05.2024	0.1	ToC of the deliverable
30.06.2024	0.1	First draft ready
09.07.2024	0.1	Draft version shared with coordination team
11.07.2024	0.2	Final version for Peer review
23.07.2024	0.3	Update after review
30.07.2024	1.0	Review and final version

## Statement of Originality

This deliverable contains original unpublished work except where clearly indicated otherwise. Acknowledgement of previously published material and of the work of others has been made through appropriate citation, quotation or both.

## Legal Disclaimer

The information in this document is provided “as is” and as it has been collected according to the inputs provided by the different partners. The above referenced consortium members shall have no liability to third parties for damage of any kind including without limitation direct, special, indirect, or consequential damages that may result from the use of these materials subject to any liability which is mandatory due to applicable law.

## Abbreviations and Acronyms

EC	European Commission
KPI	Key Performance Indicator
PGHD	Patient Generated Health Data
PPI	Patient Preference Information
PREMs	Patient-Reported Experience Measures
PROMs	Patient-Reported Outcome Measures
VBHC	Value-Based Health Care
WP	Work Package

## Table of Content

Document Control Sheet.....	2
History of Changes.....	2
Statement of Originality.....	2
Legal Disclaimer .....	2
Abbreviations and Acronyms.....	3
Table of Content .....	4
List of Figures .....	5
List of Tables .....	5
Executive Summary .....	6
1. Introduction.....	7
1.1. IMPROVE approach .....	7
1.2. Document scope and objective .....	7
2. Methodology .....	10
3. Science, Policy and Practice Trackers .....	13
3.1 Science Tracker .....	13
3.2 Policy Tracker .....	13
3.3 Practice Tracker .....	16
4 Conclusion.....	17
Appendix A .....	18
About IMPROVE .....	31
Funding Acknowledgement .....	32
Disclaimer .....	32

## List of Figures

Figure 1. From conceptualization to modelling .....	11
Figure 2. The main components of the AI/ML model design, development and validation processes .....	12

## List of Tables

Table 1: Overview of EU legislation in the Digital sector .....	14
Table 2: Overview of EU governance mechanisms and agencies in the Digital sector .....	15

## Executive Summary

This deliverable serves as a starting point and guidance in outlining of the development, execution and creation of the scientific, policies and practices tracker (T3.2). In upcoming deliverables of this series of deliverable we will provide more details on the technological aspects of the trackers and how the work can and will be automated. The outcomes of Task 3.2, which is related to the development of the scientific, policies, and practices tracker that will be integrated in the IMPROVE platform will be designed as a tool using Artificial Intelligence and Machine Learning, based on Language Learning Models, to trace updated state-of-the-art scientific methodologies, outcomes, and policies across the world and select the most important outcome on the predetermined Key Performance Indicators (KPIs) to feed WP4 and WP5. Existing data from the regions included in the consortium (in WP4) (e.g., Catalunya, Slovenia, Puglia, the Netherlands) will feed the first versions of the system in order to validate its functionalities. The tool will allow to make comparisons between regions and countries in order to identify differences across them. Data coming from WP2 will be integrated into the tracker and automatically analysed using Natural Language Processing. In addition, other Project Managers from other projects will be targeted in order to collect additional Real World Data to reinforce the development of the tool, if these project managers are allowed to share the information and data. Specifically, the development of the tracker will be based on the data collected in T2.1, T2.2, T2.3 and T2.4. as well as following the integration principles and requirements defined. A beta version of the tracker will be delivered at M12 to end users. This beta version will be refined based on users' feedback following the UCD iterative cycles, during the update and maintenance process.

**Keywords:** Scientific; Policy; Practices; Tracker; Artificial Intelligence; Machine Learning

## 1. Introduction

### 1.1. IMPROVE approach

The IMPROVE project is dedicated to harnessing the potential of Patient Generated Health Data (PGHD) through the use of m-health and e-health technologies. This initiative aims to bridge the current gaps in data utility and fragmentation by integrating and enhancing insights into the daily lives and challenges of patients across all ages who suffer from complex, chronic diseases and comorbidities. The scientific, policy, and practice trackers will be integrated into the platform to ensure a comprehensive analysis of existing activities and work done. By doing so, IMPROVE seeks to extend the capabilities of existing platforms and approaches to Patient-Centered Outcome Measures, enriching them with real-world data that reflect true patient experiences and preferences.

At the core of IMPROVE is the development of a robust platform designed to enable the intelligent use of patient input and generated evidence. This platform will facilitate three key advancements:

- **Enhancing treatment selection:** By advancing the role of patient preferences and experiences in choosing treatments, thereby personalizing healthcare to meet individual needs more effectively.
- **Medical device design improvement:** By incorporating patient feedback directly into the design process, ensuring that new medical devices are more aligned with user expectations and experiences.
- **Accelerating market entry:** By speeding up the introduction of patient-centric and cost-effective advanced integrated care solutions, thus enhancing the accessibility of innovative treatments.

The project will demonstrate the improved clinical adoption of Value-Based Health Care (VBHC) and a higher return on research and innovation investments across various European care settings. With 10 use cases spanning at least five different disease areas, including ophthalmology, oncology, cardiovascular disease, chronic inflammation, and neurology; IMPROVE will employ a diverse range of implementation strategies. These strategies are founded on a design thinking approach, which is essential for testing this innovative framework of data collection and its translation into actionable insights and controlled change.

A substantial contribution from implementation science is also anticipated, aiming to engage all relevant stakeholders to maximize the impact of the IMPROVE initiative on healthcare provision. The project's vision to integrate in-clinic and out-of-clinic PGHD and experiences to harness VBHC will be realized through improved use of Patient-Reported Outcome Measures (PROMs), Patient-Reported Experience Measures (PREMs), Patient Preference Information (PPI), and other PGHD sources. This integration will enable accelerated innovation of cost-effective and personalized patient journeys, offering accurate insights into health conditions, treatment options, and foreseeable outcomes, thus facilitating informed decision-making by patients, their families, and healthcare professionals.

### 1.2. Document scope and objective

The integration of PGHD into healthcare systems holds great promise for enhancing patient care and outcomes. Ongoing advancements in technology, supportive policies, and practical implementation strategies are crucial for maximizing the potential of PGHD. As the field evolves, continuous

collaboration among scientists, policymakers, and healthcare practitioners will be key to overcoming challenges and leveraging PGHD to its fullest extent. Therefore, the IMPROVE project, and in particular Task 3.2 will establish the scientific, policies and practices tracker to keep updated on scientific, political and practical developments.

More specific, we have seen that in scientific research several advancements in PGHD collection and utilization have been shown to be prevalent. For example,

**1. Technological Innovations:**

- Wearable devices (e.g., smartwatches, fitness trackers) and mobile health applications have significantly advanced, providing continuous, real-time health monitoring.
- Innovations in sensors and data analytics enhance the accuracy and reliability of PGHD, enabling the tracking of vital signs, physical activity, and even mental health metrics.

**2. PHGD as evidence:**

- Studies show that PGHD can improve chronic disease management by providing clinicians with comprehensive patient health data outside clinical settings.
- Research indicates that PGHD enhances patient engagement and self-management, leading to better health outcomes, especially in managing conditions like diabetes, hypertension, and heart disease.

**3. Integration with Electronic Health Records (EHR):**

- Efforts are ongoing to seamlessly integrate PGHD with EHR systems, facilitating a holistic view of patient health for providers.
- Interoperability standards, such as HL7 and FHIR, are being developed and refined to support the integration of PGHD.

Furthermore, we have seen that several Regulatory Frameworks and Guidelines have been developed the last few years in order to protect EU-citizens, and in the United States, and support the effective collection and usage of PGHD. More specific concerning,

**1. Data Privacy and Security:**

- The General Data Protection Regulation (GDPR) in Europe sets stringent requirements for data privacy, impacting how PGHD is collected, stored, and shared.
- Regulations like the Health Insurance Portability and Accountability Act (HIPAA) in the U.S. govern the use and protection of PGHD.

**2. Standardization and Interoperability:**

- Policymakers are promoting standards to ensure interoperability between PGHD sources and healthcare systems.
- Organizations such as the Office of the National Coordinator for Health Information Technology (ONC) are developing guidelines to standardize data formats and communication protocols.



### 3. Reimbursement and financial incentives:

- Policy efforts are underway to include PGHD in reimbursement models. For example, the Centers for Medicare & Medicaid Services (CMS) in the U.S. is exploring ways to incorporate remote patient monitoring into value-based care programs.
- Incentive programs, such as Meaningful Use, encourage healthcare providers to adopt technologies that support PGHD integration.

Finally, several practical implementations of PGHD are under development in order to make healthcare more efficient and effective. For example,

#### Implementation in Healthcare Settings:

##### 1. Clinical Workflows:

- Healthcare providers are incorporating PGHD into clinical workflows to enhance decision-making and personalize patient care.
- Best practices include establishing protocols for the review and action on PGHD, training staff on new technologies, and ensuring clear communication channels between patients and providers.

##### 2. Patient Engagement:

- Strategies to increase patient engagement with PGHD include education on the benefits of data sharing, simplifying data entry processes, and providing feedback on how their data impacts care decisions.
- Providers are using PGHD to empower patients in self-management programs, leveraging data to set personalized health goals and track progress.

##### 3. Challenges and Solutions:

- Common challenges include data overload for providers, ensuring data accuracy, and addressing privacy concerns.
- Solutions involve deploying advanced data analytics to filter and highlight relevant data, implementing robust verification processes, and maintaining transparent privacy practices to build patient trust.

In order to have, and keep, an overarching overview of the different scientific, policy and practice developments in the area of PGHD and the implementation of PGHD in healthcare, we will build trackers in our shared environment to keep all developments in direct reach of our consortium partners.

## 2. Methodology

During Phase 1 Conceptualising (M1-M12) of IMPROVE, the first activity of the journey is an extensive combination of desk research, systematic review, and meta-reviews (see also WP2) to identify and collect the state-of-the-art evidence and existing frameworks and models that are published, categorize it in an open-access, searchable database, using traditional (statistical analysis) and advanced analytics (AI, NLP, ML) in the Data Lab in WP3. This will allow us to build an annotated “corpus” and extract the relevant knowledge (WP3). By setting up a Data Lab using AI, NLP, and ML we are able to screen and include more information than the traditional way of screening; we can feed the framework with all state-of-the-art findings and therefore better integrate the outcome, resulting in an eclectic overview of the findings in this field.

More specifically, withing *Task 2.1 – Systematic search and creating a database* we have developed a search strategy to support an analytical framework and methodology to assess the scientific evidence on patient reported inputs and health delivery services in an iterative process to balance recall and precision. We included as many potentially relevant studies as possible, while at the same time limiting the total number of search results. We have created a **Knowledge Warehouse** with several **Chambers**, completed with a database of potentially relevant documents. A pre-trained deep learning model with a multi-language feature extractor has been developed and tested in a series of simulation studies.

The outcomes of the **Knowledge Warehouse** and its **Chambers** (1: Oncology - 1.1: Prostate cancer, 1.2: Cervical cancer, 1.3: Neck and neck cancer, 1.4: Breast cancer; 2. Ophthalmology - 2.1: Macular degeneration; 3: Cardiovascular, 3.1: Heart failure, 3.2: Coronary artery diseases, 3.3: Atrial fibrillation, 3.4: Severe aortic stenosis; 4: Neurology, 4.1: Multiple sclerosis and 5: Chronic inflammation - 5.1: Chronic rhinosinusitis), will be used to inform development of the methodologies (e.g., use cases) in the other WPs (4,5), and to build guidelines and recommendations (WP7). Based on these outcomes we will establish the experimental studies (WP4), case studies (WP5) and design science methodology (WP6).

Subsequently, we will extract the most relevant data and we will prioritize the relative significance of the different dimensions, factors and indicators (including their relative importance) for PGHD and their related concepts in Task 2.2 – Data extraction and synthesis. Furthermore, we will evaluate available models' methodologies, assessing strengths and weaknesses of selected models (1) to understand the most significant factors and indicators; (2) to profile and cluster stakeholders that are involved; and (3) to identify the context of use of the models and methodologies and their effects. As a result, we will be able to have a better overview of the effect sizes of the relationship and causality between the different patient reported inputs that will feed the development of a new methodology. Next, in *Task 2.3 - Conducting systematic reviews, desk research and potentially meta-analyses* a series of systematic reviews, desk researches and meta-analyses using the Knowledge Warehouse and its Chamber that we constructed in 2.1 and 2.2. Depending on the exact research questions that we will answer after having collected the state-of-the-art of scientific evidence (T2.1) and consultation with the consortium and other stakeholders (WP6), we will define in more detail how many systematic reviews will be conducted. Because we will use the AS Review - AI-aided tool, and Large Language Models we can easily update the search adding newly published literature and we will publish systematic reviews and meta-analyses.

For IMPROVE, this means that we can achieve a higher quality and accuracy than traditional approaches and immediately prioritize findings as well as incorporate new evidence. This process will allow us to identify and assess the available models, methods and their potential biases and how we

can IMPROVE them, for example FDA guidances for Patient Focused Drug Development<sup>1</sup> and Medical Device Development<sup>2</sup>, several IMI projects such as PREFER<sup>3</sup>, SISAQOL<sup>4</sup>, and PARADIGM<sup>5</sup>. Next, we will conduct consultation with relevant stakeholders (e.g., patients, support network of formal and informal caregivers, associations, researchers, healthcare professionals, healthcare system regulators, and industry) in a co-creation and living lab approach, in order to create consensus about these findings, including the relevance of the current models and definitions, and factors driving effective and efficient use of PGHD, to elicit stakeholder needs and capabilities in situations, contexts of use, etc (WP3). This will facilitate the identification of the knowledge gaps, strengths, and weaknesses, including the need to incorporate additional data (WP3), see also Figure 1.




Figure 1. From conceptualization to modelling

IMPROVE's conceptual model framework approach will emerge from the consensus achieved during this process and represents the starting point of Phase Modelling (M9 – M34) (WP3 – T3.1). Following the consensual definition and approach, traditional statistical analyses and advanced analytics (AI, ML, NLP) will be deployed to prioritize relevant factors that have a reciprocal relation with the database, allowing the insights gained in one task to automatically feed the other tasks. Automatic learning procedures can make use of statistical inference algorithms to produce robust models from unfamiliar or irrelevant input at a split-second, while manually conducting this work would be impossible. As a result of these exercises, a comprehensive understanding of existing frameworks will be developed, independently from the therapeutic area in a real-world context and to identify, categorize, quantify, and assess the most significant theories, models and frameworks explaining the usage of patient reported outcomes in healthcare delivery. This will also incorporate the scientific, policy and practice tracker. As a result of Phase 1, an IMPROVE framework conceptual approach will be delivered,

<sup>1</sup> <https://www.fda.gov/drugs/developmentapproval-process-drugs/fda-patient-focused-drug-development-guidance-series-enhancing-incorporationpatients-voice-medical>


<sup>2</sup> [Patient Preference Information \(PPI\) in Medical Device Decision-Making | FDA](https://www.fda.gov/medical-devices/patient-preference-information-ppl-in-medical-device-decision-making)

<sup>3</sup> <https://www.imi.europa.eu/projects-results/project-factsheets/prefer>

<sup>4</sup> <https://www.imi.europa.eu/projects-results/project-factsheets/sisaqol-imi>

<sup>5</sup> <https://imi-paradigm.eu/>

including the main components of the AI/ML model design, development, and validation process as described in the next paragraph (see Figure 2).



*Figure 2. The main components of the AI/ML model design, development and validation processes*

Data selection and management concerns the curation of measurement and data collection issues (e.g., estimation of missing values), aiming at ensuring the quality of the training set, and standard data pre-processing tasks, (e.g., aggregation, sampling, feature creation, dimensionality reduction, feature selection, discretization, and variable transformation). Model selection is the core building block of an AI/NLP/ML strategy; given a class of AI/ML models, (e.g., a kernel-based method or an expert system), its parameters are learnt by proper optimization algorithms applied on the training set, treating, in parallel, the tuning of model hyperparameters via rigid approaches, and, evaluating subsequently the model's performance on the test set using suitable performance metrics (e.g., sensitivity, specificity, positive predictive value, area under the ROC curve).

Important to mention is that this deliverable is the first of its series and will provide the basic set up and main ideas; in upcoming deliverables and throughout the project we will establish the technological needs to implement the automatization of the data collection and analyses.

### 3. Science, Policy and Practice Trackers

#### 3.1 Science Tracker

As described in the methodology, within WP2 we will conduct several systematic reviews and desk research to collect the necessary information. The outcomes of the first extensive systematic umbrella review is published in D2.1 and we will not repeat the main outcomes here. See below the training sessions for the first Screenathon where >12,000 titles and abstracts were screened to build the **Knowledge Warehouse**. Based on this Knowledge Warehouse, we have trained artificial intelligence models to identify relevant publications, a crucial step towards changes in healthcare. This is part of the Science tracker that will be built with the Large Language Models that will automatically analyze the scientific articles that will be included in the Knowledge Warehouse and its chambers. The next steps will be to evaluate the outputs and insights from these scientific papers to establish the needs for more detailed systematic reviews (e.g., focusing on randomized clinical trials, clinical trials) to define the use case studies in more detail. Subsequently the Large Language Models that have been developed will automatically analyze the most relevant outcomes to support the project.



#### 3.2 Policy Tracker

In order to collect the necessary legislative measures and policy actions that have been put in place by the European Commission and European Parliament that are relevant for the IMPROVE project, we make use of the Bruegel dataset (see here for more information - [A dataset on EU legislation for the digital world \(bruegel.org\)](https://bruegel.org/dataset-on-eu-legislation-for-the-digital-world)) that provides a comprehensive overview of mandated (by May 2024) 1) legislative measures relevant to digitalisation that were enacted in the past; measures that have been enacted during the current legislative session (2019-2024); 2) ongoing EU policy initiatives that might well lead to new legislation in the foreseeable future (see Table 1 – Overview of EU Legislations in the Digital Sector); and 3) governmental and non-governmental bodies at EU level that contribute to the implementation and enforcement of legislative measures related to digitalisation (Table 2 – Overview of EU Governance Mechanisms and Agencies in the Digital Sector).

**Table 1: Overview of EU Legislations in the Digital Sector**

Applicable law	Published in the Official Journal of the European Union
In negotiation	Proposal by the European Commission entered the legislative process.
Planned initiative	Mentioned by the European Commission as potential legislative initiative.

Research & Innovation	Industrial Policy	Connectivity	Data & Privacy	IPR	Cybersecurity	Law Enforcement	Trust & Safety	E-commerce & Consumer Protection	Competition	Media	Finance
Digital Europe Programme Regulation, (EU) 2021/564	Recovery and Resilience Facility Regulation, (EU) 2021/241	Frequency Bands Directive, (EEC) 1993/732	ePrivacy Directive, (EC) 2002/58, 2017/2018, 2017/2019, 2017/2020	Database Directive, (EC) 1996/9	Regulation for a Cybersecurity Act, (EU) 2019/1031, 2022/2513, 2022/2514	Law Enforcement Directive, (EU) 2016/680	Product Liability Directive (PLD), (EU) 2021/2115, 2022/2000, 2022/2001	Unfair Contract Terms Directive (UCTD), (EEC) 1993/13	EC Merger regulation, (EC) 2006/123	Satellite and Cable Directive, (EEC) 1993/68	Common VAT system, (EC) 2006/112, 2022/2517, 2022/2518
Horizon Europe Regulation, (EU) 2021/2020, (EU) 2021/2021	InvestEU Programme Regulation, (EU) 2021/2022	Radio Spectrum Decision, (EC) 2002/676	European Statistics, (EC) 2010/223, 2022/2517, 2022/2518	Community Design Directive, (EC) 2009/100, 2022/2517, 2022/2518	Regulation to establish a European Cybersecurity Competence Centre, (EU) 2021/1887	Directive on combating fraud and counterfeiting of non-cash means of payment, (EU) 2018/772	Toys Regulation, (EC) 2009/48, 2022/2000, 2022/2001	Price Indication Directive, (EC) 1998/6	Technology Transfer Block Exemption, (EU) 2015/6416	Information Society Directive, (EC) 2000/129	Administrative cooperation in the field of taxation, (EU) 2011/16
Regulation on a pilot regime for distributed ledger technology, (EU) 2022/3858	Connecting Europe Facility Regulation, (EU) 2021/1158	Open Internet Access Regulation, (EU) 2015/752	General Data Protection Regulation (GDPR), (EU) 2016/679	Enforcement Directive (IPR), (EC) 2004/48	NIS 2 Directive, (EU) 2022/2555	Regulation on interoperability between EU information systems in the field of borders and visas, (EU) 2018/1877	European Standardization Regulation, (EU) 2017/1372	E-commerce Directive, (EC) 2000/31	Company Law Directive, 2022/2000, 2022/2001	Audio-visual Media Services Directive (AVMSD), (EU) 2010/13	Payment Service Directive 2 (PSD2), (EU) 2015/2366, 2022/2517, 2022/2518
	Regulation on High Performance Computing Joint Undertaking, (EU) 2021/1172, 2022/2000, 2022/2001	European Electronic Communications Code Directive (EECC), (EU) 2018/1872	Regulation to protect personal data processed by EU institutions, bodies, offices and agencies, (EU) 2018/1872	Directive on the protection of trade secrets, (EU) 2016/943	Cybersecurity Regulation, (EU) 2019/2031	Regulation on terrorist content online, (EU) 2021/784	Radio Equipment Directive (RED), (EU) 2014/53	Unfair Commercial Practices Directive (UCPD), (EC) 2005/29	Market Surveillance Regulation, (EU) 2019/1020	Portability Regulation, (EU) 2017/1128	Digital Operational Resilience Act (DORA) Regulation, (EU) 2022/2554
	Regulation on Joint Undertakings under Horizon Europe, (EU) 2021/1172, 2022/2000, 2022/2001	eu top-level domain Regulation, (EU) 2019/512	Regulation on the free flow of non-personal data, (EU) 2018/1872	Design Directive, 2022/2517, 2022/2518	Information Security Regulation, 2022/2517, 2022/2518	Temporary CSAM Regulation, (EU) 2021/722, 2022/2000, 2022/2001	eIDAS Regulation (European Digital Identity Framework), (EU) 2014/4010	Directive on Consumer Rights (CRD), (EU) 2011/83	P2B Regulation, (EU) 2018/1150	Satellite and Cable II Directive, (EU) 2019/978	Crypto-assets Regulation (MICA), (EU) 2022/1116
	Decision on a path to the Digital Decade, (EU) 2022/2583	Roaming Regulation, (EU) 2022/612	Open Data Directive (PSD), (EU) 2018/1872	Computational Scoring of patents, 2022/2517, 2022/2518	Cyber Resilience Act, 2022/2517, 2022/2518	E-evidence Regulation, (EU) 2021/1154	Regulation for a Single Digital Gateway, (EU) 2021/8174	e-invoicing Directive, (EU) 2014/55	Single Market Programme, (EU) 2021/658	Copyright Directive, (EU) 2019/790	Financial Data Access Regulation, 2022/2517, 2022/2518
	European Chips Act (Regulation), (EU) 2022/1791	Union Secure Connectivity Programme, (EU) 2024/1088	Data Governance Act (DGA) Regulation, (EU) 2020/1891	Standard essential patents, 2022/2517, 2022/2518	Cyber Solidarity Act (Regulation), 2022/2517, 2022/2518	Legislation of cross-border judicial cooperation, (EU) 2022/2517	General Product Safety Regulation, (EU) 2001/18	Regulation on cooperation for the enforcement of consumer protection laws, (EU) 2017/2384	Vertical Block Exemption Regulation (VBER), (EU) 2022/772	European Media Freedom Act, (EU) 2023/1188	Payment Services Regulation, 2022/2517, 2022/2518
	Establishing the Strategic Technologies for Europe Platform (STEP), (EU) 2024/1088	Geospatial infrastructure Act, (EU) 2024/1102	European Data Act (Regulation), (EU) 2023/2854			Directive on combating violence against women, 2022/2000, 2022/2001	Machinery Regulation, (EU) 2023/1730	Geo-blocking Regulation, (EU) 2018/302	Digital Market Act (DMA) Regulation, (EU) 2022/1925	Democratization of decisions from high courts for research, study, played in the EU	Digital euro, 2022/2517, 2022/2518
	European critical raw materials act (regulation), (EU) 2022/1792	New radio spectrum policy programme (RSP), 2022/2517, 2022/2518	Interoperable Europe Act, (EU) 2024/1088			Directive for combating sexual abuse and child sexual abuse material, 2022/2000, 2022/2001	AI Act (Regulation), 2024/1188	Digital content Directive, (EU) 2019/770	Regulation on distortive foreign subsidies, (EU) 2022/2556		Regulation on combating late payment, 2022/2517, 2022/2518
	Net Zero Industry Act, 2023/2000, 2023/2001	Digital Networks Act	Regulation on data collection for short-term rental, (EU) 2023/1128			Digitalisation of small accounts	Eco-design Regulation, 2022/2000, 2022/2001	Directive on certain aspects concerning contracts for the sale of goods, (EU) 2017/771	Horizontal Block Exemption Regulations (HBER), (EU) 2022/1000, 2022/2000, 2022/2001		
	EU Science Law		European Health Data Space (Regulation), 2022/2517, 2022/2518				AI Liability Directive, 2022/2000, 2022/2001	Digital Services Act (DSA) Regulation, (EU) 2022/2005	Platform Work Directive, 2021/081, 2021/082		
			Harmonisation of GDPR enforcement procedures, 2022/2517, 2022/2518					Political Advertising Regulation, (EU) 2024/1088	Single Market Emergency Instrument (SMEI), 2022/2000, 2022/2001		
			Access to vehicle data, functions and resources					Right to repair Directive, 2022/2000, 2022/2001			
			Transparency					Consumer protection, strengthened, increased, increased			

Table 1: Overview of EU legislation in the Digital sector



**Table 2: Overview of EU governance Mechanisms and Agencies in the Digital sector**

Explanation	1 Decentralised agency	3 Independent body	7 Network of Member States
1 EU Institution	2 Governing board	4 Advisory body	8 European Standardisation Organisations

Research & Innovation	Industrial Policy	Connectivity	Data & Privacy	IPR	Cybersecurity	Law Enforcement	Trust & Safety	E-Commerce & Consumer Protection	Competition	Media	Finance
1 European Commission (DG CNCT) Unit D.1 ( <a href="#">REU 2021/0895</a> , <a href="#">REU 2021/0991</a> )	4 Governing Board of European High-Performance Computing Joint Undertaking (EuroHPC-JU) ( <a href="#">REU 2021/1173</a> )	1 European Commission (DG CNCT) Unit B.1 ( <a href="#">REU 2023/0588</a> )	2 European Health and Digital Executive Agency (HaDEA) ( <a href="#">REU 2021/1731</a> )	3 European Union Intellectual Property Office (EUIPO) ( <a href="#">REU 2011/2966</a> , <a href="#">REU 2013/1061</a> )	1 CERT-EU ( <a href="#">REU 2016/0104</a> , <a href="#">2023/2841</a> )	3 European Anti-Fraud Office (OLAF) ( <a href="#">REU 1999/352</a> )	1 European Commission (DG CNCT) AI Office ( <a href="#">2021/0106</a> )(CODE)	1 European Commission (DG JUST) Unit B.3 (Consumer Enforcement and Redress)	1 European Commission (DG CNCT) Unit F.2 & F.3 ( <a href="#">REU 2022/1925</a> , <a href="#">REU 2022/2065</a> )	1 European Board for Media Services ( <a href="#">REU 2024/1083</a> )	1 European Central Bank (ECB) ( <a href="#">REU 2015/2366</a> , <a href="#">2023/0912</a> )(CODE)
2 European Research Council Executive Agency (ERC- EA) ( <a href="#">REU 2021/1773</a> , <a href="#">REU 2021/0995</a> )	4 Governing Board of Chips Joint Undertaking (Chips-JU) ( <a href="#">2022/0033</a> )(EU)	3 Body of European Regulators for Electronic Communications (BEREC) ( <a href="#">REU 2015/2120</a> , <a href="#">REU 2018/2972</a> , <a href="#">REU 2022/012</a> )	4 European Data Protection Board (EDPB) ( <a href="#">REU 2016/0594</a> )	5 European Patent Organisation (EPO) ( <a href="#">REU 2013/1353</a> )	2 European Cybersecurity Competence Centre (ECCC) ( <a href="#">REU 2021/0897</a> )	3 EU Fundamental Rights Agency (FRA) ( <a href="#">REU 2007/1688</a> )	5 Gateway coordination group ( <a href="#">REU 2018/1724</a> )	5 European Board for Digital Services ( <a href="#">REU 2022/2065</a> )	1 European Commission (DG COMP: Antitrust)		3 European Securities and Markets Authority (ESMA) ( <a href="#">REU 2022/0958</a> , <a href="#">REU 2022/2565</a> , <a href="#">REU 2023/1114</a> )
2 European Innovation Council & SMEs Executive Agency (ISME- EA) ( <a href="#">REU 2021/1773</a> , <a href="#">REU 2021/0995</a> )	4 European Digital Infrastructure Consortium (EDIC) ( <a href="#">REU 2022/2831</a> )	3 European Union Agency for the Space Programme (EUSPA) ( <a href="#">REU 2021/0995</a> , <a href="#">REU 2023/0588</a> )	4 European Data Protection Supervisor (EDPS) ( <a href="#">REU 2018/1773</a> )	3 European Observatory on Infringements of IPR ( <a href="#">REU 2013/2366</a> )	3 European Defence Agency (EDA) ( <a href="#">REU 2015/1835</a> )	3 Europol ( <a href="#">REU 2016/7791</a> )	4 European Artificial Intelligence Board ( <a href="#">2021/0106</a> )(CODE)	7 Consumer Protection Cooperation Network (CPC) ( <a href="#">REU 2017/2394</a> )	1 European Commission (DG GROW: Unit A.4) ( <a href="#">2022/0177</a> )(CODE)		3 European Banking Authority (EBA) ( <a href="#">REU 2015/2366</a> , <a href="#">REU 2022/2565</a> , <a href="#">REU 2023/1114</a> , <a href="#">2023/0909</a> )(CODE)
2 European Research Executive Agency (REA) ( <a href="#">REU 2021/1773</a> , <a href="#">REU 2021/0995</a> )	4 European Chips Infrastructure Consortium (ECIC) ( <a href="#">REU 2023/1781</a> )	4 Governing Board of Smart Networks and Services Joint Undertaking (SNS-JU) ( <a href="#">REU 2023/2038</a> )	1 European Statistical System Committee (ESSC) ( <a href="#">REU 2009/223</a> )	5 Compulsory licences advisory body ( <a href="#">2023/0128</a> )(CODE)	1 EU Agency for Cybersecurity (ENISA) ( <a href="#">REU 2019/881</a> )	3 European Public Prosecutor's Office (EPPO) ( <a href="#">REU 2017/1839</a> )	2 European Committee for Electrotechnical Standardization (CENELEC) ( <a href="#">REU 2012/1025</a> )	7 European Consumer Centres Network ( <a href="#">REU 2021/0995</a> )	1 Advisory Committee on Restrictive Practices and Dominant Positions ( <a href="#">REU 2003/1</a> )		5 European Insurance and Occupational Pensions Authority (EIOPA) ( <a href="#">REU 2022/2565</a> , <a href="#">2023/0909</a> )(CODE)
4 European Institute of Innovation & Technology (EIT) ( <a href="#">REU 2021/1773</a> , <a href="#">REU 2021/0995</a> )	5 European Semiconductor Board ( <a href="#">REU 2023/1781</a> )	5 European Space Agency (ESA) ( <a href="#">REU 2023/0588</a> )	6 European Data Innovation Board (EDIB) ( <a href="#">REU 2022/065</a> , <a href="#">REU 2023/2854</a> )		4 European Cyber Shield ( <a href="#">2023/0106</a> )(CODE)	3 eu-LISA ( <a href="#">REU 2018/0117</a> , <a href="#">REU 2019/1727</a> )	5 European Committee for Standardization (CEN) ( <a href="#">REU 2012/1025</a> )	7 Consumer Safety Network ( <a href="#">REU 2023/2836</a> )	6 Advisory Committee on Concentrations ( <a href="#">REU 2004/138</a> )		5 Committee on Administrative Cooperation for Taxation ( <a href="#">REU 2011/130</a> )
7 European Digital Innovation Hubs Network (DIHs) ( <a href="#">REU 2021/0895</a> )	5 European Critical Raw Materials Board ( <a href="#">REU 2024/1252</a> )	3 Communications Committee (COCOM) ( <a href="#">REU 2018/1872</a> , <a href="#">REU 2023/0515</a> , <a href="#">REU 2023/012</a> )	1 Interoperable Europe Board ( <a href="#">REU 2024/031</a> )		2 European Cybersecurity Certification Group (ECCG) ( <a href="#">REU 2019/881</a> )	2 Eurojust ( <a href="#">REU 2018/1727</a> )	5 European Telecommunications Standards Institute (ETSI) ( <a href="#">REU 2012/1025</a> )		1 Contact Committee ( <a href="#">REU 2017/1122</a> )		3 VAT Committee ( <a href="#">REU 2008/112</a> , <a href="#">REU 2023/0909</a> )
	3 Net-Zero Europe Board ( <a href="#">2023/0081</a> )(CODE)	3 au Multistakeholder Advisory Group ( <a href="#">REU 2019/817</a> )	1 European Health Data Space Board (EHDS) ( <a href="#">2022/0014</a> )(CODE)		3 Interinstitutional Cybersecurity Board (ICB) ( <a href="#">REU 2024/0140</a> )	3 Frontex ( <a href="#">REU 2019/1836</a> )			1 High-Level Group on DMA ( <a href="#">REU 2023/1925</a> )		3 The Standing Committee on Administrative Cooperation ( <a href="#">REU 2022/0909</a> )
	7 European network of competence centers in semiconductors ( <a href="#">REU 2023/1781</a> )	6 Interoperable Europe Board ( <a href="#">REU 2024/031</a> )			5 NIS cooperation group ( <a href="#">REU 2022/2565</a> )	6 Interoperability Advisory Group ( <a href="#">REU 2019/817</a> )			7 European Competition Network (ECN) ( <a href="#">REU 2003/1</a> )		
					6 Interinstitutional Information Security Coordination group ( <a href="#">2022/0084</a> )(CODE)	7 European Judicial Network in criminal matters ( <a href="#">2022/0056</a> )(CODE)			7 Union Product Compliance Network ( <a href="#">REU 2019/1020</a> )		
					7 Network of National Coordination Centres ( <a href="#">REU 2021/0897</a> )						
					7 CSIRTs network ( <a href="#">REU 2022/2565</a> )						
					7 EU CyCCo ( <a href="#">REU 2022/2565</a> )						

Table 2: Overview of EU governance mechanisms and agencies in the Digital sector

During the last few years, many digital laws were enacted, mostly under the EU's Digital Agenda and Digital Single Market (DSM) programmes. In the current legislative term, which is coming to an end, important new measures relevant to digitalisation such as the Digital Markets Act (DMA), the Digital Services Act (DSA), the Data Act, the Artificial Intelligence Act (AI Act), the Data Governance Act (DGA), the European Health Data Space (EHDS), an update to the regulation on electronic identification and trust services (eIDAS 2) and a measure to strengthen the cybersecurity of critical infrastructure (NIS2) have been enacted, and most have already been published. For the current project we will follow the publications in the official outlet of the European Commission and European Parliament and keep the figures updated. The information presented in the tables, especially information about measures that have already been enacted, is based on standard, publicly available sources, based on official pronouncements of the European institutions, such as European Commission work programmes or State of the European Union addresses.

In sum, Table 1 provides an overview of legislative measures enacted, during the current legislative session, roughly following the taxonomy of de Streel and Hocepić (2019). We classify the measures depending on whether they primarily relate to (1) research and innovation; (2) industrial policy; (3) connectivity; (4) data and privacy; (5) intellectual property rights (IPR); (6) cybersecurity; (7) law enforcement; (8) trust and safety; (9) e-commerce and consumer protection; (10) competition, (11) media; and (12) finance. We distinguish among (a) measures that have been enacted, versus (b) those that are in the legislative process, versus (c) initiatives that have been announced, but that are not yet formally in the legislative process.

Table 2 provides a list and taxonomy of the governmental and non-governmental bodies that in one way or another contribute to the implementation and enforcement of EU legislative measures that relate to digitalisation. The thematic taxonomy is the same as that used in Table 1, beginning with research and innovation, and continuing with industrial policy. Only EU bodies that have a role in implementing EU law relevant to digital services are included. Member state implementation bodies are not shown, nor are any expert groups that serve solely to provide the European Commission with high-level input and advice with the drafting of delegated or implementing acts. In Table 2, we distinguish between (1) EU institutions, (2) Executive agencies, (3) Decentralised agencies, (4) Governing boards, (5) Independent bodies, (6) Advisory bodies, (7) Networks of Member States, and (8) European Standardisation Organisations (ESOs).

### 3.3 Practice Tracker

For the practice tracker we will identify practices across countries and regions, in order to develop a knowledge base of the existing practices that are conducted to develop methods or frameworks for collecting and using patient reported outcomes. Subsequently, data gathering will be done in existing repositories of good practices in different fields and with direct contacts with a wide range of leading regional and national ecosystems. Together with the project manager of these programs we will monitor the practices for a set of predefined and agreed indicators, analyse and assess the effects and efficiencies of the practices implemented that we have identified. Several European (e.g., H2020s, IHI, Horizon Europe's) and national projects and partners have already been identified, see Appendix A for the overview of recent EU-projects and beyond, associations that are linked to IMPROVE and other organizations that work in similar areas. In the upcoming months we will approach these organizations and projects to start collaborations and improve the way we work by having open conversations.



## 4 Conclusion

This deliverable summarizes the first steps in establishing and building the Scientific, Policies and Practices tracker and is a starting point and guiding outlining of the development, execution and creation of the three trackers to collect the necessary insights for the successful execution of the project, mainly feeding WP4 and WP5. First, scientific data that will be collected as a result of the systematic literature reviews and desk research we are conducting have been stored in the **Knowledge Warehouse** and are being analyzed. Data coming from WP2 will be integrated into the tracker and automatically analysed using Large Language Models, implementing NLP automatization procedures. Second, in addition, other Project Managers from other projects will be targeted (see Appendix A for a tentative list) in order to collect additional Real World Data to reinforce the development of the tool. Specifically, the development of the tracker will be based on the data collected in T2.1, T2.2. and T2.3. as well as following the integration principles and requirements defined. A beta version of the tracker will be delivered at M12 to end users. This beta version will be refined based on users' feedback following the UCD iterative cycles, during the update and maintenance process.

## Appendix A

Project or stakeholder working on PGHD	Contact details	Sort of project
DREAM Dynamic Regulation of photosynthEsis in light-Acclimated organisMs: Improving plant cultivation through disruptive technologies.	<a href="#">DREAM Project</a>	Horizon Europe
SMELODI Smart Electronic Olfaction for Body Odor Diagnostics: Advancing digitization of olfaction for disease detection and more.	<a href="#">SMELODI Project</a>	Horizon Europe
EOSC4Cancer A European-wide foundation to accelerate Data-driven Cancer Research: Integrating research data across Europe for cancer advancements.	<a href="#">EOSC4Cancer Project</a>	Horizon Europe
BioExcel-3 BioExcel Centre of Excellence for Computational Biomolecular Research: Leading in data-driven life science research.	<a href="#">BioExcel-3 Project</a>	Horizon Europe
vera.ai vera.ai: VERification Assisted by Artificial Intelligence: Combating online disinformation with AI-powered verification.	<a href="#">vera.ai Project</a>	Horizon Europe
HACID Hybrid Human Artificial Collective Intelligence in Open-Ended Decision Making: Developing a hybrid collective intelligence for decision support.	<a href="#">HACID Project</a>	Horizon Europe
BY-COVID Beyond COVID: Providing comprehensive open data on infectious diseases for monitoring and analysis.	<a href="#">BY-COVID Project</a>	Horizon Europe
TargetBRCA To develop a new targeted therapy for the treatment of naive and PARP inhibitor-resistant BRCA1/2-mutated tumors: Developing targeted therapy for aggressive tumors.	<a href="#">TargetBRCA Project</a>	Horizon Europe
4.UNCAN.eu A Coordination and Support Action to prepare UNCAN.eu platform: Generating a strategic agenda for cancer research initiative UNCAN.eu.	<a href="#">4.UNCAN.eu Project</a>	Horizon Europe
SafeHabitus STRENGTHENING FARM HEALTH AND SAFETY KNOWLEDGE AND INNOVATION SYSTEMS: Making farming safer through innovation and knowledge systems.	<a href="#">SafeHabitus Project</a>	Horizon Europe
microTOUCH Transmission of the human microbiome and its impact on health: Understanding the human microbiome's impact on health.	<a href="#">microTOUCH Project</a>	Horizon Europe
NEXTNANO NEXT GENERATION NANOPARTICLE-BASED ANTIBACTERIAL TREATMENT FOR INFECTED WOUNDS:	<a href="#">NEXTNANO Project</a>	Horizon Europe

Developing nanoparticle-based treatment for infected wounds.		
CanceRusolution A NEW DRUG TO TREAT TRIPLE NEGATIVE BREAST CANCER: Developing a new drug for Triple Negative Breast Cancer treatment.	<a href="#">CanceRusolution Project</a>	Horizon Europe
SPAC MRI Spacious and accurate MRI machines of the future: Pioneering the next generation of MRI machines for improved accessibility and accuracy.	<a href="#">SPAC MRI Project</a>	Horizon Europe
FRONTIERS Fellowship Residencies Offering science News professionals Tools and training for Independent and Ethical Reporting on Science: Establishing a program supporting science journalists' residencies in European research institutions.	<a href="#">FRONTIERS Project</a>	Horizon Europe
FOODITY FOod and nutritiOn Data-driven innovation respectful of citizen's Data Sovereignty: Promoting data-driven innovation in the food and nutrition domain while respecting data sovereignty.	<a href="#">FOODITY Project</a>	Horizon Europe
MDDDB Molecular Dynamics Data Bank. The European Repository for Biosimulation Data: Establishing a European repository for biosimulation data.	<a href="#">MDDDB Project</a>	Horizon Europe
CANCER-ID	<a href="#">CANCER-ID Project</a>	IMI
DO->IT	<a href="#">DO-&gt;IT Project</a>	IMI
DRIVE-AB	<a href="#">DRIVE-AB Project</a>	IMI
EHR4CR	<a href="#">EHR4CR Project</a>	IMI
MOPEAD	<a href="#">MOPEAD Project</a>	IMI
ROADMAP	<a href="#">ROADMAP Project</a>	IMI
VALUE-Dx	<a href="#">VALUE-Dx Project</a>	IMI
WEB-RADR	<a href="#">WEB-RADR Project</a>	IMI
MACUSTAR	<a href="#">MACUSTAR Project</a>	IMI
PRO-active	<a href="#">PRO-active Project</a>	IMI
ADVANCE	<a href="#">ADVANCE Project</a>	IMI
BD4BO	<a href="#">BD4BO Project</a>	IMI
COMPACT	<a href="#">COMPACT Project</a>	IMI
ConcePTION	<a href="#">ConcePTION Project</a>	IMI
Ebola+	<a href="#">Ebola+ Project</a>	IMI
EMIF	<a href="#">EMIF Project</a>	IMI
eTRIKS	<a href="#">eTRIKS Project</a>	IMI
EUROPAIN	<a href="#">EUROPAIN Project</a>	IMI
GETREAL	<a href="#">GETREAL Project</a>	IMI
INNODIA	<a href="#">INNODIA Project</a>	IMI
MIP-DILI	<a href="#">MIP-DILI Project</a>	IMI

Onco Track	<a href="#">Onco Track Project</a>	IMI
PARADIGM	<a href="#">PARADIGM Project</a>	IMI
Predict	<a href="#">Predict Project</a>	IMI
PreDiCT-TB	<a href="#">PreDiCT-TB Project</a>	IMI
PRISM	<a href="#">PRISM Project</a>	IMI
SAFE-T	<a href="#">SAFE-T Project</a>	IMI
SUMMIT	<a href="#">SUMMIT Project</a>	IMI
ULTRA-DD	<a href="#">ULTRA-DD Project</a>	IMI
VSV-EBOVAC	<a href="#">VSV-EBOVAC Project</a>	IMI
STRONG-AYA	<a href="#">STRONG-AYA Project</a>	HORIZON
EHAB	<a href="#">EHAB Project</a>	HORIZON
IMPROVE	<a href="#">IMPROVE Project</a>	HORIZON
LEAP	<a href="#">LEAP Project</a>	HORIZON
VELES	<a href="#">VELES Project</a>	HORIZON
Add4Kids	<a href="#">Add4Kids Project</a>	HORIZON
PeekMedAuto	<a href="#">PeekMedAuto Project</a>	HORIZON
RETINA	<a href="#">RETINA Project</a>	HORIZON
ONCOVALUE	<a href="#">ONCOVALUE Project</a>	HORIZON
DEDALUS	<a href="#">DEDALUS Project</a>	HORIZON
NANOWOUND	<a href="#">NANOWOUND Project</a>	HORIZON
Real4Reg	<a href="#">Real4Reg Project</a>	HORIZON
AI-CARE	<a href="#">AI-CARE Project</a>	HORIZON
ASCERTAIN	<a href="#">ASCERTAIN Project</a>	HORIZON
GEMINI	<a href="#">GEMINI Project</a>	HORIZON
LucidWave	<a href="#">LucidWave Project</a>	HORIZON
XpanDH	<a href="#">XpanDH Project</a>	HORIZON
Procure4Health	<a href="#">Procure4Health Project</a>	HORIZON
SUSTRONICS	<a href="#">SUSTRONICS Project</a>	HORIZON
RaRe2	<a href="#">RaRe2 Project</a>	HORIZON
AI4CMR	<a href="#">AI4CMR Project</a>	HORIZON
SYNTHEMA	<a href="#">SYNTHEMA Project</a>	HORIZON
B-specific	<a href="#">B-specific Project</a>	HORIZON
Med-IPUT	<a href="#">Med-IPUT Project</a>	HORIZON
DECIPHER	<a href="#">DECIPHER Project</a>	HORIZON
AlkaBurst2.0	<a href="#">AlkaBurst2.0 Project</a>	HORIZON
LiverPRO	<a href="#">LiverPRO Project</a>	HORIZON
SoftDesign_Orthotic	<a href="#">SoftDesign Orthotic Project</a>	HORIZON
HILIGHT	<a href="#">HILIGHT Project</a>	HORIZON
AISN	<a href="#">AISN Project</a>	HORIZON
PHOTONGATE	<a href="#">PHOTONGATE Project</a>	HORIZON
iMAClung	<a href="#">iMAClung Project</a>	HORIZON
ASSESS-DHT	<a href="#">ASSESS-DHT Project</a>	HORIZON
POINT	<a href="#">POINT Project</a>	HORIZON
SAFIR-Ready	<a href="#">SAFIR-Ready Project</a>	HORIZON
G2B-002	<a href="#">G2B-002 Project</a>	HORIZON

RadioVal	<a href="#">RadioVal Project</a>	HORIZON
CLAIMS	<a href="#">CLAIMS Project</a>	HORIZON
U-BiomarCARE	<a href="#">U-BiomarCARE Project</a>	HORIZON
IDERHA	<a href="#">IDERHA Project</a>	HORIZON
SIMPLI-DEMO	<a href="#">SIMPLI-DEMO Project</a>	HORIZON
greenerRPP	<a href="#">greenerRPP Project</a>	HORIZON
TransPharm	<a href="#">TransPharm Project</a>	HORIZON
GenHumCap	<a href="#">GenHumCap Project</a>	HORIZON
CONNECTINGHEALTH	<a href="#">CONNECTing the dots withIN diGital HEALTH Innovation Ecosystems Project</a>	HORIZON
SMILE	<a href="#">SMILE Project</a>	HORIZON
PAINS	<a href="#">PAINS Project</a>	HORIZON
MULTI-SOFT	<a href="#">MULTI-SOFT Project</a>	HORIZON
SAFIRE	<a href="#">SAFIRE Project</a>	HORIZON
HD-BRECA Integrating longitudinal multi-modal profiling of metastatic breast cancer patients for high-definition oncology		HORIZON
EndoTheranostics Multi-sensor Eversion Robot Towards Intelligent Endoscopic Diagnosis and Therapy	<a href="#">Link</a>	HORIZON
SyMPaBiome Development of a synbiotic product to modulate the Parkinson's disease associated microbiome	<a href="#">Link</a>	HORIZON
TARAF Taxonomy and azole resistance in Aspergillus section Flavi	<a href="#">Link</a>	HORIZON
MAESTRO Novel machine learning techniques to improve the forecasting of stroke post-interventive outcomes	<a href="#">Link</a>	HORIZON
PROTECT PReparing for Optimal Phase III/IV maTernal Group B StreptococCal vaccine Trials in Africa (PROTECT)	<a href="#">Link</a>	HORIZON
TLSaRNA Artificial induction of tertiary lymphoid structures (TLS) in tumors using intratumoral mRNAs to evaluate its synergy with immune checkpoint inhibitors	<a href="#">Link</a>	HORIZON
POINT Preventing non-communicable diseases caused by the post-acute phase of cOvid-19 INfecTion	<a href="#">Link</a>	HORIZON
xShare Expanding the European EHRxF to share and effectively use health data within the EHDS	<a href="#">Link</a>	HORIZON
CVDLINK A federated paradigm of real-world data sources utilization for the empowerment of diagnosis, prognosis and risk assessment of cardiovascular conditions	<a href="#">Link</a>	HORIZON

MONALISA A SIOPEX pragmatic clinical trial to MONitor Neuroblastoma relapse with Liquid biopsy Sensitive Analysis	<a href="#">Link</a>	HORIZON
LIMORD Longitudinal Integrative Models for Online Relapse Detection	<a href="#">Link</a>	HORIZON
PaLaDiN Patient Lifestyle and Disease Data Interactium	<a href="#">Link</a>	HORIZON
SASICU Improving patient outcomes and reducing cognitive load of clinical staff in intensive care through medical-device interoperability and an open and secure IT ecosystem	<a href="#">Link</a>	HORIZON
BRCA-RLT Impact of BRCA2 deficiency on the DNA damage response and Immunogenicity of Prostate cancer after Radioligand therapy	<a href="#">Link</a>	HORIZON
MPX-RESPONSE A clinical research network to improve the management of Monkeypox virus disease	<a href="#">Link</a>	HORIZON
CARE1 First line randomized study platform to optimize treatment in patients with metastatic renal cell carcinoma	<a href="#">Link</a>	HORIZON
CompSURG Computational Methods to Analyse Intra-operative Adverse Events in Surgery at Scale	<a href="#">Link</a>	HORIZON
IMPACT- AML Master Framework and Pragmatic Clinical Trial for Relapse or Refractory Acute Myeloid Leukemia	<a href="#">Link</a>	HORIZON
Murnia Prevention of Radiotherapy and Chemotherapy Induced Oromucosal Wounds Using an Oral Application Gel: Murnia® Mouth Gel	<a href="#">Link</a>	HORIZON
CCI4EU COMPREHENSIVE CANCER INFRASTRUCTURES 4 EUROPE	<a href="#">Link</a>	HORIZON
LIVERATION Unravelling the impact of Radiofrequency in liver surgery: the key to decrease local recurrence?	<a href="#">Link</a>	HORIZON
CO-CAPTAIN CANCER PREVENTION AMONG INDIVIDUALS WITH MENTAL ILL-HEALTH: CO-ADAPTING AND IMPLEMENTING PATIENT NAVIGATION FOR PRIMARY CANCER PREVENTION	<a href="#">Link</a>	HORIZON
EXHEUSVITAL ECONOMIC, LEGAL AND IP FEASIBILITY STUDIES OF EXHEUS VITAL TEST	<a href="#">Link</a>	HORIZON
Sagittarius A PRECISION MEDICINE TRIAL LEVERAGING BLOOD-BASED TUMOR GENOMICS TO OPTIMIZE TREATMENT IN	<a href="#">Link</a>	HORIZON

OPERABLE STAGE III AND HIGH-RISK STAGE II COLON CANCER PATIENTS - THE SAGITTARIUS TRIAL		
ELGN-GI A first-in-class therapy for intestinal malabsorption in premature newborns	<a href="#">Link</a>	HORIZON
TRUSTroke TRUSTWORTHY AI FOR IMPROVEMENT OF STROKE OUTCOMES	<a href="#">Link</a>	HORIZON
CLAIMS CLinical impact through AI-assisted MS care	<a href="#">Link</a>	HORIZON
IDERHA Integration of heterogeneous Data and Evidence towards Regulatory and HTA Acceptance	<a href="#">Link</a>	HORIZON
InDx CMC Implant The InDx CMC Implant. A new treatment for thumb base joint arthritis.	<a href="#">Link</a>	HORIZON
ERA4Health Fostering a European Research Area for Health Research	<a href="#">Link</a>	HORIZON
MAGIC Minimally invasive reliable Glucose monitoring in Intensive Care	<a href="#">Link</a>	HORIZON
PAT4CGT Automated online monitoring & control to improve processes and decision making in cell and gene therapy manufacturing	<a href="#">Link</a>	HORIZON
UNDINE The human genetic and immunological determinants of the clinical manifestations of SARS-CoV-2 infection: Towards personalised medicine	<a href="#">Link</a>	HORIZON
EOSC4Cancer A European-wide foundation to accelerate Data-driven Cancer Research	<a href="#">Link</a>	HORIZON
PRIME Prime editing to Repair Inherited Metabolic Errors: in vivo gene correction for human genetic disease	<a href="#">Link</a>	HORIZON
VEMOtion Assistive Medical Robotics for Very Early Mobilization of Critical Care Patients	<a href="#">Link</a>	HORIZON
aortoseal A minimally invasive and durable endograft fastening solution for Abdominal Aortic Aneurysm (AAA)	<a href="#">Link</a>	HORIZON
EUonQoL Quality of Life in Oncology: measuring what matters for cancer patients and survivors in Europe	<a href="#">Link</a>	HORIZON
ONCOVALUE Implementing value-based oncology care at European cancer hospitals: An AI-based framework for assessing real-life effectiveness of novel cancer therapies in real-time	<a href="#">Link</a>	HORIZON
SBMP-microcarrier SBMP - disrupting the manufacturing of biological drugs through a	<a href="#">Link</a>	HORIZON

ground-breaking nanotechnology-based microcarrier		
SYNTHEMA Synthetic generation of hematological data over federated computing frameworks	<a href="#">Link</a>	HORIZON
AI CUREs AI to predict Cancer metastasis using Ultra-Echo-Sono imaging	<a href="#">Link</a>	HORIZON
EChLiBRiST Development and validation of a quantitative point-of-care test for the measurement of severity biomarkers to improve risk stratification of fever syndromes and enhance child survival	<a href="#">Link</a>	HORIZON
TRUMPET TRUStworthy Multi-site Privacy Enhancing Technologies	<a href="#">Link</a>	HORIZON
MyPath Developing and implementing innovative Patient-Centred Care Pathways for cancer patients	<a href="#">Link</a>	HORIZON
SafePolyMed Improve Safety in Polymedication by Managing Drug-Drug-Gene Interactions	<a href="#">Link</a>	HORIZON
MitoSen Detection and elimination of senescent cells targeting Cyclophilin D	<a href="#">Link</a>	HORIZON
END-VOC ENDING COVID 19 VARIANTS OF CONCERN THROUGH COHORT STUDIES: END-VOC	<a href="#">Link</a>	HORIZON
X-MiND Next generation X-ray/H+ Micro and Nano Scintillating Detectors	<a href="#">Link</a>	HORIZON
STEPUPIORS TWINNING FOR A EUROPEAN CONSORTIUM OF RECTAL CANCER RESEARCH INSTITUTIONS THROUGH STEPPING UP SCIENTIFIC, TECHNOLOGICAL AND INNOVATION EXCELLENCE OF IORS	<a href="#">Project Link</a>	HORIZON
RE-SHIFT Dismantling, REdialing, personalizing, and implementing task SHIFTing psychosocial interventions to treat and prevent common mental disorders in low-resource settings	<a href="#">Project Link</a>	HORIZON
AMICAS Adaptive Multi-Drug Infusion Control System for General Anesthesia in Major Surgery	<a href="#">Project Link</a>	HORIZON
Ganymed Next-generation surgical robotics to set a new standard of care in orthopaedic surgery	<a href="#">Project Link</a>	HORIZON
HyperProbe Transforming brain surgery by advancing functional-guided neuronavigational imaging	<a href="#">Project Link</a>	HORIZON
EPIVINF Epigenetic regulation of host factors in viral infections (EPIVINF)	<a href="#">Project Link</a>	HORIZON



StrokeAlert- WomenEU Striking Stroke-enhancing and expanding StrokeAlert's business skills	<a href="#">Project Link</a>	HORIZON
RMCmplxPheno Recurrent miscarriage as a complex phenotype: Harnessing large-scale clinical data to uncover underlying biological pathways	<a href="#">Project Link</a>	HORIZON
MINIGRAPH Minimally Invasive Neuromodulation Implant and implantation procedure based on ground-breaking GRAPHene technology for treating brain disorders	<a href="#">Project Link</a>	HORIZON
XTremedy Medical Developing a surgical infection treatment to reduce amputations, healing times and hospital stays for diabetic foot patients	<a href="#">Project Link</a>	HORIZON
MEETMUSA Accelerating the iMPact of microsurgEry by upscaling production of thE world's first microsurgical roboT: MUSA	<a href="#">Project Link</a>	HORIZON
HyperCollar4D Radical Improvement of Cancer Treatment without Additional Negative Side Effects	<a href="#">Project Link</a>	HORIZON
RNhale Dry Powder Formulation of RNA Nanoparticles for Inhalation and Improved Storage and Transport Conditions	<a href="#">Project Link</a>	HORIZON
ResisCHIP Rapid chip-based detection of antibiotic resistances	<a href="#">Project Link</a>	HORIZON
CANDY Therapeutic discovery for cholangiocellular carcinoma	<a href="#">Project Link</a>	HORIZON
HIPPOX The mechanobiology of hypoxia during bone regeneration	<a href="#">Project Link</a>	HORIZON
RESEMBLE Long-read sequencing to resolve the missing heritability in patients suspected of PTEN hamartoma tumour syndrome	<a href="#">Project Link</a>	HORIZON
HERVCOV SARS-CoV-2-induced activation of pathogenic endogenous retrovirus envelope HERV-W: towards personalized treatment of COVID-19 patients	<a href="#">Project Link</a>	HORIZON
eCREAM enabling Clinical Research in Emergency and Acute care Medicine through automated data extraction	<a href="#">Project Link</a>	HORIZON
TransPharm Transforming into a sustainable European pharmaceutical sector	<a href="#">Project Link</a>	HORIZON
STRONG-AYA THE STRONG-AYA INITIATIVE: IMPROVING THE FUTURE OF YOUNG ADULTS WITH CANCER	<a href="#">Project Link</a>	HORIZON

eCAP eCAP - Ehealth CAPsule for digestive disease diagnostics and therapy	<a href="#">Project Link</a>	HORIZON
SAFEST Improving quality and patient SAFETY in surgical care through STandardisation and harmonisation of perioperative care in Europe	<a href="#">Project Link</a>	HORIZON
D-SOLVE Understanding the individual host response against Hepatitis D Virus to develop a personalized approach for the management of hepatitis D	<a href="#">Project Link</a>	HORIZON
ebeam4therapy Very High Energy Electrons Beam for Radiotherapy	<a href="#">Project Link</a>	HORIZON
IDEAHL Improving Digital Empowerment for Active Healthy Living	<a href="#">Project Link</a>	HORIZON
TROPHY ulTRaFast hOlograPHic FTIR microscopy	<a href="#">Project Link</a>	HORIZON
Edit-SMM EARLY DETECTION AND INTERVENTION IN SMOLDERING MULTIPLE MYELOMA: POPULATION-BASED SCREENING AND TREATMENT	<a href="#">Project Link</a>	HORIZON
IMPROVING-GT Innovative strategies to increase engraftment of engineered hematopoietic stem cells and bypass genotoxic conditioning, toward the next-generation gene therapy		HORIZON
Dermatology and Venereology	<a href="#">UEMS-EBDV European Board of Dermato-Venereology</a>	
Emergency Medicine		
Endocrinology	<a href="#">uems-endocrinology – Informational website for UEMS-Endocrinology members</a>	
Gastroenterology & Hepatology	<a href="#">EBGH (eubogh.org)</a>	
Geriatrics	<a href="#">Geriatric Medicine - Section of the UEMS (uemsgeriatricmedicine.org)</a>	
Gynaecology & Obstetrics	<a href="#">EBCOG - European Board &amp; College of Obstetrics and Gynaecology Home</a>	
Infectious Diseases		
Internal Medicine		
Laboratory Medicine	<a href="#">-UEMS SLM   News (uems-slm.org)</a>	
Medical Biopathology		

Medical Genetics	<a href="http://uems-genetics.org">UEMS - Section of Medical Genetics - Home (uems-genetics.org)</a>	
Medical Microbiology	<a href="http://uems-smm.eu">Home   UEMS Section of Medical Microbiology (uems-smm.eu)</a>	
Medical Oncology		
Nephrology		
Neurology	<a href="http://uems-neuroboard.org">UEMS Section of Neurology - Home (uems-neuroboard.org)</a>	
Neurosurgery		
Nuclear Medicine	<a href="http://uems.eanm.org">uems.eanm.org</a>	
Occupational Medicine	<a href="http://uems-occupationalmedicine.org">UEMS   Occupational Medicine (uems-occupationalmedicine.org)</a>	
Ophthalmology	<a href="http://uems-ophtalmologie.org">UEMS - Section of Ophthalmology - Welcome to our Website (uems-ophtalmologie.org)</a>	
Oro-Maxillo-Facial Surgery	<a href="http://OMFSUEMS">OMFSUEMS</a>	
Orthopaedics & Traumatology	<a href="http://uems-ortho.org">UEMS Specialist Section of Orthopaedics and Traumatology (uems-ortho.org)</a>	
Otorhinolaryngology	<a href="http://orluems.com">UEMS ORL SECTION - (orluems.com)</a>	
Paediatric Surgery	<a href="http://uemspaedsurg.org">UEMS - Section of Paediatric Surgery (uemspaedsurg.org)</a>	
Paediatrics	<a href="http://eapaediatrics.eu">EAP - European Academy of Paediatrics   EAP - European Academy of Paediatrics (eapaediatrics.eu)</a>	
Pathology	<a href="http://wordpress.com">About   UEMS – Section of Pathology (wordpress.com)</a>	
Pharmacology	<a href="http://uems-pharmacology.eu">UEMS Section of Pharmacology (uems-pharmacology.eu)</a>	
Physical and Rehabilitation Medicine	<a href="http://uems-prm.eu">The European Union of Medical Specialists UEMS PRM Section and Board (uems-prm.eu)</a>	
Plastic, Reconstructive and Aesthetic Surgery	<a href="http://EBOPRAS">Welcome to EBOPRAS</a>	
Pneumology		
Psychiatry	<a href="http://uemspsychiatry.org">UEMS Section of Psychiatry (uemspsychiatry.org)</a>	

Public Health Medicine		
Radiology	<a href="http://uemsradiology.eu">Homepage - European Union of Medical Specialists (uemsradiology.eu)</a>	
Radiation Oncology and Radiotherapy		
Rheumatology	<a href="http://uemsrheumatology.eu">Rheumatology - Home (uemsrheumatology.eu)</a>	
Surgery	<a href="http://uemssurg.org">UEMS Section of Surgery (uemssurg.org)</a>	
Thoracic Surgery	<a href="http://uemsthorax.eu">Thoracic Surgery - Home (uemsthorax.eu)</a>	
Urology	<a href="http://ebu.eu">EBU   EBU</a>	
Vascular Surgery	<a href="http://uemsvascular.com">UEMS – Section and Board of Vascular Surgery (uemsvascular.com)</a>	
Column 2: Specialist Divisions		
Reproductive Medicine		
Angiology/Vascular medicine	<a href="http://uems-vas-int.eu">UEMS - Vas-Int Angiology Vascular Medicine</a>	
Neuroradiology	<a href="http://uemsradiology.eu">Homepage - European Union of Medical Specialists (uemsradiology.eu)</a>	
Interventional Radiology	<a href="http://uemsir.eu">UEMS   Division of Interventional Radiology - UEMS   Division of Interventional Radiology (uemsir.eu)</a>	
Abdominal wall surgery (working group)	<a href="http://uemssurg.org">Abdominal Wall Surgery – UEMS Section of Surgery (uemssurg.org)</a>	
Breast surgery	<a href="http://uemssurg.org">Breast Surgery – UEMS Section of Surgery (uemssurg.org)</a>	
Coloproctology	<a href="http://uemssurg.org">Coloproctology – UEMS Section of Surgery (uemssurg.org)</a>	
Emergency surgery	<a href="http://uemssurg.org">Emergency Surgery – UEMS Section of Surgery (uemssurg.org)</a>	
Endocrine surgery	<a href="http://uemssurg.org">Endocrine Surgery – UEMS Section of Surgery (uemssurg.org)</a>	
General surgery	<a href="http://uemssurg.org">General Surgery EBSQ Exam – UEMS Section of Surgery (uemssurg.org)</a>	

Hepato-pancreato-biliary surgery	<a href="http://uemssurg.org">HPB Surgery – UEMS Section of Surgery (uemssurg.org)</a>	
Minimal invasive surgery (working group)		
Surgical oncology	<a href="http://uemssurg.org">Surgical Oncology – UEMS Section of Surgery (uemssurg.org)</a>	
Transplant surgery	<a href="http://uemssurg.org">Transplant Surgery – UEMS Section of Surgery (uemssurg.org)</a>	
Transplant coordination		
Transplant immunology		
Transplant medicine		
Trauma surgery	<a href="http://uemssurg.org">Trauma Surgery – UEMS Section of Surgery (uemssurg.org)</a>	
Column 3: Multidisciplinary Joint Committees		
Adolescent Medicine		
Breast Care		
Hand Surgery	<a href="http://ebhs.info">European Board of Hand Surgery (ebhs.info)</a>	
Immune Mediated Disease		
Infection Control		
Intensive Care Medicine	<a href="http://esicm.org">The European Board of Intensive Care Medicine » EBICM (esicm.org)</a>	
Manual Medicine		
Network of Accredited Skills Centers in Europe (NASCE)	<a href="http://nascenet.org">NASCE - Home (nascenet.org)</a>	
Oncology		
Pain Medicine		
Paediatric Urology	<a href="http://espu.org">EBPU/MJC-PU/EAPU - ESPU   European Society for Paediatric Urology</a>	
Phlebology		
Rare & Undiagnosed Diseases	<a href="http://pte.hu">U.E.M.S. - Multidisciplinary Joint Committee - Rare and Undiagnosed Diseases   U.E.M.S. - Multidisciplinary Joint Committee - Rare and Undiagnosed Diseases (pte.hu)</a>	
Sexual Medicine	<a href="http://mjcsm.org">MJCSM – Multidisciplinary Committee of Sexual Medicine</a>	
Spine Surgery		
Sports Medicine		

Upper gastro-intestinal surgery	<a href="http://uemssurg.org">Upper Gastrointestinal Surgery – UEMS Section of Surgery (uemssurg.org)</a>	
Wound Healing	<a href="http://mjcwoundhealing.org">mjcwoundhealing.org</a>	
Column 4: Thematic Federations		
CESMA (Council for European Specialists Medical Assessment)	<a href="#">Main UEMS - CESMA</a>	
EDI - Equality, Diversity, Inclusivity		
Green and Sustainable Medical Practice		
Hypertension		
Legal and Forensic Medicine		
Medical Ethics		
Vertigo		

## About IMPROVE

IMPROVE aims to be a dynamic, ready-to-use framework for seamlessly integrating patient-reported information. This adaptable system constantly evolves with the latest evidence, using PGHD and health system data to provide cost-effective solutions for diverse treatment conditions in real settings. The project follows Ontology, Epistemology, and Methodology principles. Ontology defines structures in patient-reported outcomes; Epistemology ensures valid knowledge; Methodology links techniques to outcomes, systematically addressed in its work.

IMPROVE optimizes patient-reported information in real settings, offering a deep understanding of patient behaviors. The project sets up ontology, epistemology, and methodology to minimize the burden on stakeholders cost-effectively. It adopts a scalable, data-driven approach with NLP-driven knowledge extraction. Real World Data is integrated into the Federated Causal Evidence module for comprehensive understanding. Evidence collected enables visualizing attributes affecting patient-reported outcomes through IMPROVE Engagement Factors and Indicators Knowledge Graphs.

IMPROVE's toolkit includes resources for decision-makers, featuring plausible scenarios via the Copenhagen Method. Patient engagement via the MULTI-ACT model ensures sustainable healthcare aligned with patient priorities. This project delivers a modular, open access strategy, providing a trustworthy ecosystem of evidence-based applications. Patient engagement and co-creation scenarios solidify its role in transforming healthcare research and care.

## Funding Acknowledgement

This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No. The JU receives support from the European Union's Horizon Europe research and innovation programme and COCIR, EFPIA, EuropaBio, MedTech Europe, Vaccines Europe, and the contributing partners Universidad Politecnica de Madrid (UPM), PredictBy (PBY), Danish Medicine Agency (DKMA), Roche (ROCHE), Institute for Economic Research (IER), Copenhagen Institute for Futures Studies (CIFS), Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Philips Medical System Nederland BV (PMSN), Heinrich-Heine-Universitaet Duesseldorf (UDUS), Tilburg University (TiU), Dedalus (DEDA), Fondazione Italiana Sclerosi Multipla Fism Onlus (FISM), ARESS Puglia (ARSS), MultiMed (MM)iserundschmidt GmbH (ius), Better (BET), The Netherlands Cancer Institute (NKI), University of Applied Sciences St. Pölten (STPUAS), Eye Hospital, University Medical Centre Ljubljana (EYE), Utrecht University (UU), UDG Alliance (UDGA), Medtronic Iberica SA (MDT), Fundacio Hospital Universitari Vall D'Hebron – Institut de Recerca (VHIR), Splosna Bolnisnica Celje (SBC), ORTOPEDSKA BOLNIŠNICA VALDOLTRA (OBV), ETHNIKO KENTRO EREVNAS KAI TECHNOLOGIKIS ANAPTYXIS (CERTH).

## Disclaimer

Funded by the European Union, the private members, and those contributing partners of the IHI JU. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them.

[www.ih.europa.eu](http://www.ih.europa.eu)

## Supporters of the Innovative Health Initiative Joint Undertaking:





## Project partners:

Coordinator



Associated Partner

